MicroRNAs as predictive biomarkers of response to tyrosine
kinase inhibitor therapy in metastatic renal cell carcinoma

J 2018

MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

KOVÁČOVÁ, Júlia, A. POPRACH, T. BUCHLER, W.C. CHO, Ondřej SLABÝ et. al.

Základní údaje

Originální název

MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

Autoři

KOVÁČOVÁ, Júlia (703 Slovensko, domácí), A. POPRACH (203 Česká republika), T. BUCHLER (203 Česká republika), W.C. CHO (156 Čína) a Ondřej SLABÝ (203 Česká republika, garant, domácí)

Vydání

Clinical Chemistry and Laboratory medicine, BERLIN, WALTER DE GRUYTER & CO, 2018, 1434-6621

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.638

Kód RIV

RIV/00216224:14740/18:00106934

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1515/cclm-2017-0861

UT WoS

000440934600017

Klíčová slova anglicky

miRNAs; prediction; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 3. 2019 16:20, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Renal cell carcinoma (RCC) accounts for 2%-3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miR-NAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.

Návaznosti

NV15-34678A, projekt VaV

Název: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

Citovat

KOVÁČOVÁ, Júlia, A. POPRACH, T. BUCHLER, W.C. CHO a Ondřej SLABÝ. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. Clinical Chemistry and Laboratory medicine. BERLIN: WALTER DE GRUYTER & CO, 2018, roč. 56, č. 9, s. 1426-1431. ISSN 1434-6621. Dostupné z: https://dx.doi.org/10.1515/cclm-2017-0861.

@article{1443078,
   author = {Kováčová, Júlia and Poprach, A. and Buchler, T. and Cho, W.C. and Slabý, Ondřej},
   article_location = {BERLIN},
   article_number = {9},
   doi = {http://dx.doi.org/10.1515/cclm-2017-0861},
   keywords = {miRNAs; prediction; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor},
   language = {eng},
   issn = {1434-6621},
   journal = {Clinical Chemistry and Laboratory medicine},
   title = {MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma},
   url = {https://www.degruyter.com/view/j/cclm.2018.56.issue-9/cclm-2017-0861/cclm-2017-0861.xml},
   volume = {56},
   year = {2018}
}

TY  - JOUR
ID  - 1443078
AU  - Kováčová, Júlia - Poprach, A. - Buchler, T. - Cho, W.C. - Slabý, Ondřej
PY  - 2018
TI  - MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma
JF  - Clinical Chemistry and Laboratory medicine
VL  - 56
IS  - 9
SP  - 1426-1431
EP  - 1426-1431
PB  - WALTER DE GRUYTER & CO
SN  - 14346621
KW  - miRNAs
KW  - prediction
KW  - renal cell carcinoma
KW  - sunitinib
KW  - tyrosine kinase inhibitor
UR  - https://www.degruyter.com/view/j/cclm.2018.56.issue-9/cclm-2017-0861/cclm-2017-0861.xml
N2  - Renal cell carcinoma (RCC) accounts for 2%-3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miR-NAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.
ER  -

KOVÁČOVÁ, Júlia, A. POPRACH, T. BUCHLER, W.C. CHO a Ondřej SLABÝ. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. \textit{Clinical Chemistry and Laboratory medicine}. BERLIN: WALTER DE GRUYTER \&{}amp; CO, 2018, roč.~56, č.~9, s.~1426-1431. ISSN~1434-6621. Dostupné z: https://dx.doi.org/10.1515/cclm-2017-0861.

Podrobný výpis o publikaci